No Data
Trending Industry Today: WUXI BIO Leads Gains In Biotechnology Stocks
FDA Approves Shanghai Henlius Biotech's Investigational New Drug Application for Anti-Neurodegenerative Disease Drug
FOSUN PHARMA (02196.HK): HENLIUS plans to conduct the Phase I clinical trial of HLX99 in the USA when conditions permit.
On February 10, Gelonghui reported that FOSUN PHARMA (02196.HK) announced that its holding subsidiary, Shanghai HENLIUS Biotechnology Co., Ltd and its holding subsidiaries (hereinafter collectively referred to as "HENLIUS") recently received approval from the USA FDA (i.e., the United States Food and Drug Administration) to initiate clinical trials for HLX99. HENLIUS plans to conduct Phase I clinical trials for HLX99 in the USA once conditions are met. HLX99 is an innovative small-molecule conjugated chemical drug independently developed by the group, intended for the treatment of Amyotrophic Lateral Sclerosis (ALS). As of December 2024, the group currently
Shanghai Henlius Biotech's HLX99 Receives FDA Approval for ALS Treatment
Shanghai Henlius Biotech Doses First Patient in Phase 2 HLX43 Trial
HENLIUS (02696.HK): The phase II clinical study of HLX43 (a PD-L1 targeted antibody - novel DNA topoisomerase I inhibitor conjugate) for the treatment of recurrent/metastatic esophageal squamous cell carcinoma (ESCC) has completed its first patient dosing
On February 10, Gelonghui reported that HENLIUS (02696.HK) announced the recent administration of the first patient in a phase II clinical study of the injectable HLX43 (a PD-L1 targeted antibody - a new DNA topoisomerase I inhibitor conjugate) in patients with recurrent/metastatic esophageal squamous cell carcinoma in mainland China (excluding Hong Kong, Macau, and Taiwan). The company also plans to conduct relevant phase II clinical trials for potential indications such as cervical cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, head and neck squamous cell carcinoma, and non-small cell lung cancer when conditions permit. The study aims to evaluate different doses of HLX43.
